Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT
Company Participants
Jan van de Winkel – Co-Founder, President & CEO
Tahamtan Ahmadi – Executive VP, Chief Medical Officer & Head of Experimental Medicines
Anthony Pagano – Executive VP & CFO
Judith Klimovsky – Executive VP & Chief Development Officer
Conference Call Participants
Jonathan Chang – Leerink Partners LLC, Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Asthika Goonewardene – Truist Securities, Inc., Research Division
Judah Frommer – Morgan Stanley, Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Qize Ding – Rothschild & Co Redburn, Research Division
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Sebastiaan van der Schoot
Presentation
Operator
Hello to Genmab’s conference call regarding its proposed acquisition of Merus. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects.
Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities, in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy. I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
Jan van de Winkel
Co-Founder, President & CEO
Hello, and thank you for joining us. Today, we are sharing a transformative step for Genmab, our planned acquisition of Merus. With me today to present this exciting news is our Chief Medical Officer, Tahi Ahmadi, who
#Genmab #GMAB #Call #Transcript